Press Release

Qubit Pharmaceuticals announces the appointment of Robin Chaudret, a renowned expert in molecular modeling, as Chief Technology Officer

Qubit Pharmaceuticals, a deeptech company specializing in the discovery of new drug candidates through simulation and molecular modeling accelerated by hybrid HPC and quantum computing, announces the appointment of Dr. Robin Chaudret as its new Chief Technology Officer. At 40 years old, Robin Chaudret is an accomplished scientist and executive in the fields of computational chemistry, molecular modeling, and in silico drug discovery.

From 2017 to 2024, he worked at Schrödinger Inc., a leading global company in the development of scientific software used by many players in the pharmaceutical and biotechnology industries to accelerate drug discovery through molecular modeling and simulation. During his seven years at Schrödinger, he progressed from account manager to Executive Director, overseeing the management and development of commercial strategies and coordinating a cross-functional, multidisciplinary team for strategic clients, thus contributing to Schrödinger’s growth in the pharmaceutical and biotechnology sectors. Prior to that, he worked (2013 to 2017) as a researcher at Scienomics, a company specializing in materials simulation and modeling.

Robin Chaudret is a graduate of École Normale Supérieure (2009) and holds a PhD in computational chemistry from Pierre and Marie Curie University (UPMC) in Paris, co-supervised by Jean-Philip Piquemal, co-founder of Qubit Pharmaceuticals. His doctoral research focused on the multiscale modeling of cations (positive ions) of heavy metals and the development of polarizable force fields. His postdoctoral research includes studying enzymatic reaction mechanisms at Duke University in the United States and developing methods for in silico enzymatic engineering at IFP Energies Nouvelles.

Throughout his career, Robin Chaudret has written 28 scientific publications and gained extensive experience in molecular dynamics, quantum mechanics-molecular mechanics (QM/MM), and force field development. His work spans several fields, including pharmaceuticals, biotechnology, materials science, and chemical modeling, making him a versatile and forward-thinking leader.

Robin’s arrival will enable Qubit Pharmaceuticals to advance even more rapidly in applying cutting-edge technologies and sciences to molecular modeling to create new drug candidates that address real-world needs.

Robert Marino, CEO of Qubit Pharmaceuticals, states: “We are thrilled to welcome Dr. Robin Chaudret to our team. His academic background and professional experience, particularly at Schrödinger, demonstrate his expertise in computational chemistry, molecular modeling, and in silico drug discovery. His appointment is a valuable asset to help Qubit Pharmaceuticals strengthen its leadership and implement its strategic vision.”